Official Title
Prospective, One Center, Four Groups, Open, Comparative, Controlled Study to Explore T Cells Response to SARS COV 2 Peptides by Metabolic Activity Method in Convalesce and Healthy Individuals Versus Antibody Response
Brief Summary

The analysis method described in this protocol is a novel simple plausible immunological approach which is non-invasive, high throughput, real-time quantitative monitoring of metabolic activity (MA) profiles of fresh Peripheral Blood Mononuclear Cells (PBMC) in response to various reagents at different concentrations. The purpose of this study is to evaluate the T cells reactivity to SARS COV 2 immunogenic selected peptides by Metabolic Activity Method in convalesce and healthy individuals and to compare it with Antibody response (ELISA) and clinical information

Detailed Description

This is a prospective, four groups, open, comparative, controlled study. A total of 400
completed, evaluated subjects will be enrolled in this study. Main Study Measures: Reactivity
of T cells to selected SARS COV-2 peptides by MA test and IgG Antibody response to SARS COV-2
by commercial ELISA test.

Study Procedures:

- Screening

- Informed consent signing

- Medical history review

- Blood collection.

- MA test and ELISA test will be performed at Savicell's Laboratory site.

Unknown status
COVID19
Corona Virus Infection

Diagnostic Test: Savicell's ImmunoBiopsy™

ImmunoBiopsy and ELISA

Eligibility Criteria

Inclusion Criteria:

- All recruited subjects are between 18 to 90 years old.

- All recruited subjects read the informed consent and then signed the informed consent.

- All recruited subjects filled out the questionnaire form

Exclusion Criteria:

- Subject has active infection or inflammation determined clinically at screening.

- Subject is currently treated with concomitant medication related directly or can
affect the immune system as steroids.

- Subject has impaired judgment.

- Known positive HIV, hepatitis B, or hepatitis C, autoimmune disease.

- Known history of a significant medical disorder, which in the investigators' judgment
contraindicates the patient's participation.

- Drug or alcohol abuse

- Subject is participating in any other clinical trial for drug investigation within 10
days prior sample collection

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Israel
Locations

Carmel Medical Center
Haifa, North, Israel

Investigator: Yochai Adir, Prof
Contact: 972-0506-265820
yochaiad@clalit.org.il

Contacts

Yochai Adir, Prof
+972-0506-265820
yochaiad@clalit.org.il

Shafrira Shai, PhD, Study Director
Savicell Diagnostics Ltd

Savicell Diagnostics Ltd
NCT Number
Keywords
COV-19
T Cells
COV-2 PEPTIDE
MeSH Terms
Coronavirus Infections